Cambria Investment Management’s United Therapeutics UTHR Stock Holding History

Cambria Investment Management’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$301K	Buy	556 +40	+8%	+$22.5K	0.01%	595
2026 Q1	$306K	Sell	516 -226	-30%	-$113K	0.02%	509
2025 Q4	$362K	Sell	742 -1,915	-72%	-$892K	0.02%	459
2025 Q3	$1.11M	Buy	2,657 +460	+21%	+$155K	0.07%	205
2025 Q2	$631K	Sell	2,197 -39	-2%	-$11.7K	0.04%	213
2025 Q1	$689K	Buy	2,236 +1,162	+108%	+$398K	0.05%	159
2024 Q4	$379K	Sell	1,074 -118	-10%	-$43.4K	0.02%	288
2024 Q3	$427K	Buy	+1,192	New	+$403K	0.03%	247
2015 Q4	–	Sell	-150	Closed	-$20K	–	267
2015 Q3	$20K	Buy	+150	New	+$24.1K	0.01%	221

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Cambria Investment Management's UTHR Position: Q2 2026 in Review

Cambria Investment Management increased its United Therapeutics (UTHR) stake by 7.8% in Q2 2026, buying an estimated $22.5K and bringing the position to 556 shares worth $301K. The position accounts for 0.01% of the portfolio, ranked #595.

Cambria Investment Management first reported a position in UTHR in Q3 2015 and has held it in 9 quarters since. The position peaked at $1.11M in Q3 2025. 878 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Cambria Investment Management held 556 shares of United Therapeutics worth $301K as of Q2 2026.
Cambria Investment Management bought 40 United Therapeutics shares in Q2 2026, an estimated $22.5K.
United Therapeutics made up 0.01% of Cambria Investment Management's portfolio in Q2 2026, its #595 holding.
Cambria Investment Management first reported a position in United Therapeutics in Q3 2015 and has held it in 9 quarters since.
Cambria Investment Management's United Therapeutics position peaked at $1.11M in Q3 2025.
878 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Cambria Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.